McEwan, Phil

Conceptualizing a Model: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2

Roberts, M., Russell, L. B., Paltiel, A. D., Chambers, M., McEwan, P., & Krahn, M. (2012) · Value in Health

Health Systems, Economic Evaluations, Quality of LifeDelphi Technique in Research

Cited by 241

Weight loss and risk reduction of obesity-related outcomes in 0·5 million people: evidence from a UK primary care database

Haase, C. L., Lopes, S., Olsen, A. H., Satylganova, A., Schnecke, V., & McEwan, P. (2021) · International Journal of Obesity

Obesity, Physical Activity, DietDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 199

Real-world associations of renin-angiotensin-aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom

Linde, C., Bakhai, A., Furuland, H., Evans, M., McEwan, P., Ayoubkhani, D., & Qin, L. (2019) · Journal of the American Heart Association

Potassium and Related DisordersRenin-Angiotensin System Studies

Cited by 110

Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence

McEwan, P., Bennett, H., Khunti, K., Wilding, J., Edmonds, C., Thuresson, M., Wittbrodt, E., Fenici, P., & Kosiborod, M. (2020) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementHealth Systems, Economic Evaluations, Quality of Life

Cited by 58

Body mass index and risk of obesity‐related conditions in a cohort of 2.9 million people: Evidence from a UK primary care database

Haase, C. L., Eriksen, K. T., Lopes, S., Satylganova, A., Schnecke, V., & McEwan, P. (2021) · Obesity Science & Practice

Obesity, Physical Activity, DietDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 57

The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: an economic evaluation using data from the DECLARE-TIMI 58 trial

McEwan, P., Morgan, A. R., Boyce, R., Bergenheim, K., Gause‐Nilsson, I. A. M., Bhatt, D. L., Leiter, L. A., Johansson, P. A., Mosenzon, O., Cahn, A., et al. (2021) · Diabetes, Obesity and Metabolism

Health Systems, Economic Evaluations, Quality of LifeDiabetes Treatment and Management

Cited by 34

The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss

Rowe, R., Cowx, M., Poole, C., McEwan, P., Morgan, C., & Walker, M. (2005) · Current Medical Research and Opinion

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 28